K1-70 - A Phase I, Single Ascending Intramuscular Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs K1 70 (Primary)
- Indications Graves' disease
- Focus Adverse reactions; First in man
- Sponsors AV7
- 12 Dec 2017 Planned End Date changed from 1 Apr 2017 to 1 Feb 2020.
- 12 Dec 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2020.
- 28 Sep 2016 New trial record